Sara Elizabeth Dolan Looby, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 8 | 2023 | 1659 | 2.450 |
Why?
|
| HIV Infections | 55 | 2023 | 17531 | 2.160 |
Why?
|
| Hot Flashes | 3 | 2019 | 330 | 1.370 |
Why?
|
| Perimenopause | 3 | 2020 | 142 | 1.290 |
Why?
|
| Nursing Research | 1 | 2024 | 79 | 0.860 |
Why?
|
| Sweetening Agents | 2 | 2022 | 291 | 0.800 |
Why?
|
| Cultural Diversity | 1 | 2024 | 370 | 0.690 |
Why?
|
| Poverty | 2 | 2022 | 2714 | 0.660 |
Why?
|
| HIV | 5 | 2023 | 1587 | 0.630 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2020 | 420 | 0.570 |
Why?
|
| Aging | 6 | 2023 | 8725 | 0.500 |
Why?
|
| Plaque, Atherosclerotic | 6 | 2023 | 1529 | 0.490 |
Why?
|
| Body Composition | 17 | 2019 | 2441 | 0.480 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 2782 | 0.430 |
Why?
|
| Cardiovascular Diseases | 9 | 2023 | 15645 | 0.390 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 3249 | 0.360 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 4 | 2020 | 137 | 0.330 |
Why?
|
| Monocytes | 2 | 2016 | 2591 | 0.330 |
Why?
|
| Coronary Artery Disease | 8 | 2023 | 6544 | 0.320 |
Why?
|
| Patient Selection | 2 | 2020 | 4248 | 0.310 |
Why?
|
| Asymptomatic Diseases | 5 | 2018 | 586 | 0.300 |
Why?
|
| Quality of Life | 7 | 2021 | 13463 | 0.290 |
Why?
|
| Lipoproteins, LDL | 3 | 2022 | 643 | 0.290 |
Why?
|
| Female | 65 | 2024 | 396141 | 0.290 |
Why?
|
| Patient Participation | 1 | 2017 | 1447 | 0.290 |
Why?
|
| Intra-Abdominal Fat | 4 | 2019 | 624 | 0.290 |
Why?
|
| Amino Acids | 3 | 2020 | 1709 | 0.280 |
Why?
|
| Stress, Psychological | 2 | 2022 | 4527 | 0.280 |
Why?
|
| Testosterone | 5 | 2007 | 2495 | 0.280 |
Why?
|
| Anxiety | 2 | 2020 | 4669 | 0.260 |
Why?
|
| Carotid Artery, Common | 2 | 2006 | 172 | 0.260 |
Why?
|
| Vulnerable Populations | 2 | 2022 | 717 | 0.250 |
Why?
|
| Atherosclerosis | 7 | 2023 | 3419 | 0.250 |
Why?
|
| Depressive Disorder | 1 | 2018 | 3712 | 0.250 |
Why?
|
| Adipose Tissue | 6 | 2020 | 3314 | 0.240 |
Why?
|
| Primary Health Care | 1 | 2022 | 4736 | 0.240 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 3690 | 0.240 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 686 | 0.240 |
Why?
|
| Health Promotion | 1 | 2017 | 2208 | 0.240 |
Why?
|
| Education, Nursing, Graduate | 1 | 2024 | 13 | 0.230 |
Why?
|
| Humans | 72 | 2024 | 765926 | 0.230 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 4418 | 0.220 |
Why?
|
| Middle Aged | 44 | 2023 | 223016 | 0.220 |
Why?
|
| Resilience, Psychological | 2 | 2021 | 808 | 0.210 |
Why?
|
| Women's Health | 3 | 2022 | 2081 | 0.200 |
Why?
|
| Nucleosides | 1 | 2022 | 130 | 0.200 |
Why?
|
| Adiponectin | 1 | 2006 | 1120 | 0.170 |
Why?
|
| Integrases | 1 | 2022 | 520 | 0.170 |
Why?
|
| Fibrosis | 2 | 2018 | 2073 | 0.170 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 618 | 0.160 |
Why?
|
| Research Personnel | 1 | 2024 | 589 | 0.160 |
Why?
|
| Adult | 43 | 2023 | 223088 | 0.160 |
Why?
|
| Sex Factors | 6 | 2019 | 10611 | 0.150 |
Why?
|
| Inflammation | 7 | 2023 | 10843 | 0.150 |
Why?
|
| United States | 9 | 2024 | 72909 | 0.150 |
Why?
|
| Health Education | 2 | 2019 | 1060 | 0.150 |
Why?
|
| Adiposity | 2 | 2019 | 1891 | 0.150 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 285 | 0.150 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 26282 | 0.150 |
Why?
|
| Reproduction | 2 | 2020 | 645 | 0.150 |
Why?
|
| Lipodystrophy | 2 | 2005 | 145 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 1729 | 0.140 |
Why?
|
| Androgens | 2 | 2005 | 1278 | 0.140 |
Why?
|
| Comorbidity | 3 | 2023 | 10575 | 0.140 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2019 | 352 | 0.140 |
Why?
|
| Bone Density | 4 | 2007 | 3491 | 0.130 |
Why?
|
| Patient Compliance | 2 | 2018 | 2693 | 0.130 |
Why?
|
| Body Weight | 3 | 2007 | 4627 | 0.130 |
Why?
|
| Hospitals, General | 1 | 2020 | 803 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 14745 | 0.130 |
Why?
|
| Subcutaneous Fat | 1 | 2019 | 401 | 0.120 |
Why?
|
| Body Image | 1 | 2020 | 645 | 0.120 |
Why?
|
| HIV Wasting Syndrome | 1 | 2005 | 99 | 0.120 |
Why?
|
| Serum | 1 | 2016 | 205 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2020 | 1181 | 0.110 |
Why?
|
| Program Development | 1 | 2020 | 1297 | 0.110 |
Why?
|
| Absorptiometry, Photon | 2 | 2019 | 1707 | 0.110 |
Why?
|
| Aged | 9 | 2022 | 171163 | 0.110 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2015 | 393 | 0.110 |
Why?
|
| Coronary Vessels | 2 | 2016 | 3094 | 0.110 |
Why?
|
| Anti-Retroviral Agents | 2 | 2018 | 1786 | 0.110 |
Why?
|
| Angiography | 2 | 2016 | 1589 | 0.110 |
Why?
|
| Anti-HIV Agents | 6 | 2020 | 4558 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2018 | 1899 | 0.110 |
Why?
|
| Tunica Media | 2 | 2011 | 107 | 0.110 |
Why?
|
| Blood Coagulation Disorders | 1 | 2016 | 351 | 0.110 |
Why?
|
| Pericardium | 1 | 2018 | 679 | 0.110 |
Why?
|
| Income | 1 | 2021 | 1874 | 0.100 |
Why?
|
| Hyperinsulinism | 1 | 2005 | 402 | 0.100 |
Why?
|
| Community Health Services | 1 | 2017 | 657 | 0.100 |
Why?
|
| Weight Loss | 2 | 2003 | 2710 | 0.090 |
Why?
|
| Psychotherapy | 1 | 2020 | 1648 | 0.090 |
Why?
|
| Male | 29 | 2023 | 363815 | 0.090 |
Why?
|
| Tunica Intima | 2 | 2011 | 455 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 609 | 0.090 |
Why?
|
| Regression Analysis | 7 | 2018 | 6321 | 0.090 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1865 | 0.090 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2005 | 391 | 0.090 |
Why?
|
| Body Mass Index | 7 | 2022 | 13042 | 0.090 |
Why?
|
| Residence Characteristics | 1 | 2020 | 2116 | 0.090 |
Why?
|
| Exercise | 3 | 2021 | 5936 | 0.090 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2004 | 407 | 0.090 |
Why?
|
| Cognition | 2 | 2021 | 7043 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2021 | 3136 | 0.080 |
Why?
|
| Pyrazines | 1 | 2015 | 1204 | 0.080 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 639 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 1348 | 0.080 |
Why?
|
| Obesity | 2 | 2015 | 13082 | 0.080 |
Why?
|
| Complementary Therapies | 1 | 2003 | 486 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 970 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2006 | 2586 | 0.070 |
Why?
|
| Fingers | 1 | 2011 | 509 | 0.070 |
Why?
|
| Cohort Studies | 6 | 2023 | 41680 | 0.070 |
Why?
|
| Hormones | 2 | 2006 | 865 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 20690 | 0.070 |
Why?
|
| Women | 1 | 2009 | 225 | 0.070 |
Why?
|
| Risk Factors | 14 | 2023 | 74850 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2003 | 886 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 2331 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2011 | 932 | 0.070 |
Why?
|
| Neck | 1 | 2011 | 735 | 0.070 |
Why?
|
| Mental Health | 1 | 2020 | 3272 | 0.060 |
Why?
|
| Depression | 3 | 2020 | 8223 | 0.060 |
Why?
|
| Stroke | 2 | 2018 | 9739 | 0.060 |
Why?
|
| HIV-1 | 2 | 2020 | 6945 | 0.060 |
Why?
|
| Triglycerides | 3 | 2013 | 2440 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2005 | 4959 | 0.060 |
Why?
|
| Vitamin D | 1 | 2019 | 3272 | 0.060 |
Why?
|
| Self Efficacy | 1 | 2009 | 641 | 0.060 |
Why?
|
| Boston | 5 | 2023 | 9334 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2023 | 12417 | 0.060 |
Why?
|
| Aldosterone | 1 | 2009 | 881 | 0.060 |
Why?
|
| Social Support | 3 | 2022 | 2190 | 0.060 |
Why?
|
| Sleep | 1 | 2020 | 4818 | 0.060 |
Why?
|
| Attitude to Health | 2 | 2009 | 2020 | 0.060 |
Why?
|
| Lipids | 3 | 2018 | 3317 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2018 | 3988 | 0.060 |
Why?
|
| Menstruation | 2 | 2006 | 310 | 0.060 |
Why?
|
| Massachusetts | 3 | 2023 | 8882 | 0.050 |
Why?
|
| Telemedicine | 1 | 2020 | 3108 | 0.050 |
Why?
|
| Lipid Metabolism | 2 | 2015 | 1893 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 747 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 10380 | 0.050 |
Why?
|
| Nursing Audit | 1 | 2022 | 13 | 0.050 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2023 | 127 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2011 | 5987 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2023 | 11508 | 0.050 |
Why?
|
| Viral Load | 3 | 2006 | 3385 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 8037 | 0.050 |
Why?
|
| Age Factors | 1 | 2017 | 18382 | 0.040 |
Why?
|
| Health Status | 1 | 2003 | 4085 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2018 | 54807 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2007 | 871 | 0.040 |
Why?
|
| Smoking | 2 | 2013 | 9082 | 0.040 |
Why?
|
| Home Care Services | 1 | 2006 | 658 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2007 | 2002 | 0.040 |
Why?
|
| Infant Food | 1 | 2019 | 139 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2021 | 251 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2006 | 936 | 0.040 |
Why?
|
| Young Adult | 7 | 2020 | 59857 | 0.040 |
Why?
|
| Adolescent | 10 | 2018 | 88811 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 4423 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 3801 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2020 | 297 | 0.040 |
Why?
|
| Phenotype | 1 | 2016 | 16714 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 608 | 0.040 |
Why?
|
| Quinolines | 1 | 2023 | 769 | 0.040 |
Why?
|
| Glucose Clamp Technique | 1 | 2018 | 262 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2006 | 6202 | 0.040 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2018 | 260 | 0.030 |
Why?
|
| C-Reactive Protein | 2 | 2006 | 3851 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2019 | 434 | 0.030 |
Why?
|
| Cholesterol | 1 | 2006 | 2902 | 0.030 |
Why?
|
| Tomography, X-Ray | 1 | 2016 | 58 | 0.030 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2018 | 198 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2018 | 238 | 0.030 |
Why?
|
| Metformin | 1 | 2004 | 904 | 0.030 |
Why?
|
| Osteoporosis | 2 | 2007 | 1582 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 3430 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2016 | 194 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2006 | 271 | 0.030 |
Why?
|
| Lumbar Vertebrae | 2 | 2006 | 1878 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 543 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2006 | 4186 | 0.030 |
Why?
|
| Calcifediol | 1 | 2006 | 156 | 0.030 |
Why?
|
| Galectins | 1 | 2018 | 293 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2019 | 934 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2022 | 8724 | 0.030 |
Why?
|
| Risk Assessment | 4 | 2018 | 24275 | 0.030 |
Why?
|
| Femur Neck | 1 | 2006 | 316 | 0.030 |
Why?
|
| Cholesterol, LDL | 2 | 2015 | 2395 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2006 | 731 | 0.030 |
Why?
|
| North America | 1 | 2017 | 1287 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2018 | 736 | 0.030 |
Why?
|
| International Cooperation | 1 | 2020 | 1433 | 0.030 |
Why?
|
| Energy Intake | 2 | 2007 | 2141 | 0.030 |
Why?
|
| Heart Failure | 1 | 2017 | 11837 | 0.030 |
Why?
|
| Cholesterol, HDL | 2 | 2013 | 1813 | 0.030 |
Why?
|
| Program Evaluation | 2 | 2009 | 2502 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2006 | 616 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2018 | 1186 | 0.030 |
Why?
|
| Minority Groups | 1 | 2020 | 1208 | 0.030 |
Why?
|
| Blood Glucose | 3 | 2015 | 6422 | 0.030 |
Why?
|
| Physical Endurance | 2 | 2006 | 368 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2003 | 504 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2023 | 2645 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2018 | 8530 | 0.020 |
Why?
|
| Thorax | 1 | 2005 | 554 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2004 | 712 | 0.020 |
Why?
|
| Prevalence | 2 | 2020 | 15828 | 0.020 |
Why?
|
| Self-Help Groups | 1 | 2003 | 194 | 0.020 |
Why?
|
| Pandemics | 2 | 2022 | 8721 | 0.020 |
Why?
|
| Placebos | 1 | 2016 | 1659 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2020 | 2866 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 3106 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 1787 | 0.020 |
Why?
|
| Ovary | 1 | 2005 | 961 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2004 | 738 | 0.020 |
Why?
|
| Europe | 1 | 2017 | 3430 | 0.020 |
Why?
|
| Anthropometry | 1 | 2005 | 1339 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2019 | 22228 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 2662 | 0.020 |
Why?
|
| Health Behavior | 1 | 2022 | 2649 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 318 | 0.020 |
Why?
|
| Time Factors | 3 | 2018 | 40097 | 0.020 |
Why?
|
| Nursing Education Research | 1 | 2009 | 11 | 0.020 |
Why?
|
| Halfway Houses | 1 | 2009 | 11 | 0.020 |
Why?
|
| Hyperemia | 1 | 2011 | 223 | 0.020 |
Why?
|
| Femur | 1 | 2006 | 1309 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2009 | 64 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2003 | 706 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 12059 | 0.020 |
Why?
|
| Incidence | 2 | 2018 | 21513 | 0.020 |
Why?
|
| Life Style | 1 | 2021 | 3928 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2018 | 65194 | 0.020 |
Why?
|
| Safe Sex | 1 | 2009 | 144 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 457 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 2925 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2018 | 3225 | 0.020 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2008 | 91 | 0.020 |
Why?
|
| Hip Joint | 1 | 2004 | 1000 | 0.020 |
Why?
|
| Body Constitution | 1 | 2007 | 272 | 0.020 |
Why?
|
| Estradiol | 1 | 2004 | 1947 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 1936 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 770 | 0.020 |
Why?
|
| Liver | 1 | 2021 | 7559 | 0.020 |
Why?
|
| Weight Gain | 1 | 2005 | 2356 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2894 | 0.010 |
Why?
|
| Diet | 2 | 2007 | 8087 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2007 | 292 | 0.010 |
Why?
|
| Peptides | 1 | 2006 | 4331 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 2513 | 0.010 |
Why?
|
| Focus Groups | 1 | 2009 | 1458 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2007 | 1325 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 13273 | 0.010 |
Why?
|
| Body Size | 1 | 2005 | 460 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2009 | 1187 | 0.010 |
Why?
|
| Urban Population | 1 | 2009 | 2040 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 4909 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 36426 | 0.010 |
Why?
|
| Curriculum | 1 | 2009 | 3784 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2005 | 3678 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 6941 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 4055 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 7842 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 81537 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 8522 | 0.010 |
Why?
|
| Hypertension | 1 | 2011 | 8616 | 0.010 |
Why?
|
| Insulin | 1 | 2004 | 6603 | 0.010 |
Why?
|